Asterias BioTherapeutics, Inc. has appointed Georgia Erbez chief financial officer (CFO) – effective Nov. 9. Erbez has served as financial consultant to various biotech companies and most recently was CFO, secretary, and treasurer of Raptor Pharmaceutical Corp. Prior to this, she was managing director, healthcare investment banking at Collins Stewart, a senior level investment banker at Beal Advisors, Jeffries & Company, Inc. and Cowen and Company
Asterias Appoints CFO
Listen to this article
Asterias BioTherapeutics, Inc. has appointed Georgia Erbez chief financial officer (CFO) – effective Nov. 9. Erbez has served as financial consultant to various biotech companies and most recently was CFO, secretary, and treasurer of Raptor Pharmaceutical Corp. Prior to this, she was managing director, healthcare investment banking at Collins Stewart, a senior level investment banker at Beal Advisors, Jeffries & Company, Inc. and Cowen and Company
Keep up with the top pharma business news of the week. On the go.
More from Business
• By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
• By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
